Halozyme Therapeutics, Inc.
corporate_fare Company Profile
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for HALO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for HALO spans 8-K, 144, 10-Q.
Recent high-impact activity:
- German Appeals Court Overturns Keytruda SC Injunction; Halozyme Shares Slip
- FDA Grants Accelerated Approval to J&J's ENHANZE-Based RYBREVANT FASPRO in Head and Neck Cancer
- Halozyme Q3 Revenue Jumps 39% to $493M, Full-Year 2026 Guidance Raised
- Halozyme Posts $2.01 Q3 EPS as Royalty Engine Keeps Rolling
- Halozyme Wins Injunction Blocking Merck's Keytruda SC in Europe
Financial Snapshot
Short Interest & Short Volume
6.81 days to coverFINRA reported short interest of 13,650,219 shares in HALO as of the October 30, 2026 settlement, unchanged from the prior period — about 6.8 days to cover at its recent average daily volume. On November 20, 2026, 46.1% of HALO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for HALO, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.
Upsized $1.3B Convertible Notes Priced · Conversion Terms Set at 27.5% Premium
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →